Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors.
- DOI
- 10.3390/jcm12020399
- Published
- 2023 Jan 4
- Container
- Journal of clinical medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/jcm12020399,
title = {Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors.},
author = {Guidetti F and Arribas AJ and Sartori G and Spriano F and Barnabei L and Tarantelli C and Von Roemeling R and Martinez E and Zucca E and Bertoni F},
year = {2023},
journal = {Journal of clinical medicine},
doi = {10.3390/jcm12020399},
url = {https://doi.org/10.3390/jcm12020399}
}RIS
TY - JOUR TI - Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors. AU - Guidetti F AU - Arribas AJ AU - Sartori G AU - Spriano F AU - Barnabei L AU - Tarantelli C AU - Von Roemeling R AU - Martinez E AU - Zucca E AU - Bertoni F PY - 2023 JO - Journal of clinical medicine DO - 10.3390/jcm12020399 UR - https://doi.org/10.3390/jcm12020399 ER -
APA
F, G., AJ, A., G, S., F, S., L, B., C, T., R, V. R., E, M., E, Z., & F, B. (2023). Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors.. Journal of clinical medicine. https://doi.org/10.3390/jcm12020399
Source records
- pubmed · retrieved 2026-09-26T19:11:30.606Z